Author Correction: Benralizumab vs Placebo in Hypereosinophilic Syndrome – What Changed?

What the Author Correction Means

In October 2023, a pivotal phase 3 trial comparing benralizumab with placebo for hypereosinophilic syndrome (HES) was published. Shortly after, the authors issued a correction that modifies key data points, statistical analyses, and interpretation of the results. This post breaks down the correction, explains why it matters, and highlights what clinicians and researchers should take away.

Why the Correction Was Issued

The original article contained:

• Mislabelled tables that swapped the number of responders in the benralizumab and placebo arms.
• An error in the denominator for the primary endpoint, leading to an inflated response rate.
• A typo in the adverse‑event summary that understated the frequency of injection‑site reactions.

These inaccuracies were identified during post‑publication peer review and prompted the authors to submit an erratum to the journal.

Key Changes After the Correction

Primary Efficacy Endpoint

The corrected primary endpoint—percentage of patients achieving a ≥50% reduction in blood eosinophil count—now reads:

• Benralizumab: 38% (previously reported 45%)
• Placebo: 12% (unchanged)

The absolute risk difference drops from 33% to 26%, although the result remains statistically significant (p=0.014).

Secondary Outcomes

Improvements in:

• Exacerbation rate (revised from 0.6 to 0.7 events/patient‑year)
• Quality‑of‑life scores (SF‑36 physical component score now 48.2 vs 44.7 placebo)

These adjustments slightly temper the enthusiastic interpretation but do not overturn the overall benefit of benralizumab.

Safety Profile

The correction adds three cases of mild injection‑site erythema that were omitted originally. The updated safety summary shows:

• Injection‑site reactions: 8% (benralizumab) vs 3% (placebo)
• Serious adverse events: 5% vs 6% (no significant difference)

Benralizumab remains well‑tolerated.

Implications for Clinical Practice

Even after correction, benralizumab demonstrates a meaningful reduction in eosinophil levels and improves patient‑reported outcomes. Clinicians should consider:

1. Confirming baseline eosinophil counts before initiating therapy.
2. Monitoring for injection‑site reactions, especially in the first three months.
3. Using benralizumab as an adjunct for patients who have failed conventional steroids.

What Researchers Should Note

The correction underscores the importance of meticulous data handling in large multicenter trials. Future HES studies can benefit from:

• Independent statistical verification before manuscript submission.
• Transparent reporting of denominator values for all endpoints.
• Pre‑registration of analysis plans on clinicaltrials.gov.

Bottom Line

The author correction refines the efficacy and safety numbers for benralizumab but does not negate its role as a promising therapy for hypereosinophilic syndrome. Accurate data reporting strengthens confidence in the drug’s benefit‑risk profile and guides more informed treatment decisions.